Committee advances bill to shield identities of lethal‑injection suppliers over FOIA concerns

Senate Bill 464, presented by Sen. Hester, would expand statutory secrecy for the identities and supply chain of lethal‑injection drugs and create a class‑D felony for reckless disclosure. The committee heard pointed opposition from open‑government advocates and public‑health commentators but advanced the bill on a roll call vote, 5–3.

Supporters, including the Attorney General’s office, framed the bill as a practical response to earlier procurement disputes and Supreme Court questions: it aims to protect suppliers from public exposure that has previously blocked or delayed executions. Brian Bowman, a deputy attorney general, said the proposal provides stronger penalties to deter reckless disclosures that could prevent the state from obtaining drugs.

Opponents said secrecy invites litigation, creates a black market and conflicts with transparency obligations. Sonny Alvarado of the Arkansas Freedom of Information Coalition and Faranda Brasfield recalled Arkansas’s 2017 experience, when controversial drug procurement drew litigation from companies and disrupted planned executions. Public‑interest lawyers argued criminalizing disclosure in the statute could chill lawful petitioning and lawsuits; one witness said the bill could make aggrieved manufacturers reluctant to sue because disclosure of the supply chain could be criminalized.

The committee adopted the bill after debate. The roll call recorded support from a five‑member majority and the bill was reported out of committee. The transcript shows the Attorney General’s office argued the state could raise sovereign‑immunity defenses and that litigation is likely, but the committee approved the measure nonetheless.

What’s next: With committee approval, SB 464 advances to the next stage of the legislative process. Opponents indicated they expect litigation over both statutory secrecy and any procurement actions that rely on concealed suppliers.